Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review Committee
Scheller and Sdhof will serve as key R&D leaders supporting the advancement of Alectors research pipeline and proprietary drug discovery platform.
- Scheller and Sdhof will serve as key R&D leaders supporting the advancement of Alectors research pipeline and proprietary drug discovery platform.
- He is currently the Chairman of Research and Development at BridgeBio, and previously held executive leadership positions at 23andMe and Genentech.
- In a short time, Alector has made tremendous progress with several programs in the clinic, and many more to follow shortly behind.
- The Companys product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimers disease.